ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

Evelina A Zimovetz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.